Literature DB >> 2775615

The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa.

D R Robertson1, N D Wood, H Everest, K Monks, D G Waller, A G Renwick, C F George.   

Abstract

1. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa was investigated in young and elderly healthy volunteers. 2. The plasma clearance of levodopa following intravenous administration of 50 mg was 14.2 +/- 2.8 (s.d.) ml min-1 kg-1 in the elderly compared with 23.4 +/- 4.1 ml min-1 kg-1 in the young (P less than 0.01) which resulted in a 49% greater area under the plasma concentration-time curve (AUC) in the older subjects (P less than 0.01). The volume of distribution (Vss) was lower in the elderly (1.01 +/- 0.29 l kg-1) than in the young (1.65 +/- 0.39 l kg-1) (P less than 0.002). 3. Following oral administration of 250 mg of levodopa the AUC was 2512 +/- 588 ng ml-1h in the elderly compared with 1056 +/- 282 ng ml-1h in the young (P less than 0.002). Cmax was also significantly greater in the elderly (P less than 0.05). The bioavailability of levodopa was significantly greater in the elderly (0.63 +/- 0.12 compared with 0.41 +/- 0.16, P less than 0.01). 4. In the presence of carbidopa, the plasma clearance of intravenous levodopa (50 mg) was reduced in both age groups but remained lower in the elderly (5.8 +/- 0.9 ml min-1 kg-1 compared with 9.3 +/- 1.0 ml min-1 kg-1; P less than 0.01). This resulted in a 54% greater AUC in the older subjects (P less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2775615      PMCID: PMC1379971          DOI: 10.1111/j.1365-2125.1989.tb03506.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

1.  THE EFFECT OF INCREASING AGE ON THE DISTRIBUTION OF PERIPHERAL BLOOD FLOW IN MAN.

Authors:  A D BENDER
Journal:  J Am Geriatr Soc       Date:  1965-03       Impact factor: 5.562

2.  Effects of levodopa therapy in patients with Parkinson's disease: statistical evidence for reduced tolerance to levodopa in the elderly.

Authors:  B Grad; J Wener; G Rosenberg; S W Wener
Journal:  J Am Geriatr Soc       Date:  1974-11       Impact factor: 5.562

3.  Variability of L-dopa absorption in man.

Authors:  D N Wade; P T Mearrick; D J Birkett; J Morris
Journal:  Aust N Z J Med       Date:  1974-04

4.  Levodopa for parkinsonism in elderly and demented patients.

Authors:  G A Broe; F I Caird
Journal:  Med J Aust       Date:  1973-03-31       Impact factor: 7.738

5.  Effects of L-dopa administration of the concentrations of dopa, dopamine and norepinephrine in various rat tissues.

Authors:  J A Romero; L D Lytle; L A Ordonez; R J Wurtman
Journal:  J Pharmacol Exp Ther       Date:  1973-01       Impact factor: 4.030

6.  Catecholamine metabolism during oral administration of levodopa.

Authors:  H Hinterberger; C J Andrews
Journal:  Arch Neurol       Date:  1972-03

7.  Adult lean body mass declines with age: some longitudinal observations.

Authors:  G B Forbes; J C Reina
Journal:  Metabolism       Date:  1970-09       Impact factor: 8.694

8.  Absorption and metabolism of levodopa.

Authors:  W B Abrams; C B Coutinho; A S Leon; H E Spiegel
Journal:  JAMA       Date:  1971-12-27       Impact factor: 56.272

9.  The assessment of the amount of fat in the human body from measurements of skinfold thickness.

Authors:  J V Durnin; M M Rahaman
Journal:  Br J Nutr       Date:  1967-08       Impact factor: 3.718

10.  Incidence of side effects from levodopa during the introduction of treatment.

Authors:  R B Godwin-Austen; C C Frears; S Bergmann
Journal:  Br Med J       Date:  1971-01-30
View more
  38 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

2.  The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers.

Authors:  D R Robertson; I Higginson; B S Macklin; A G Renwick; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

3.  Effects of Parkinson's Disease on Fundamental Frequency Variability in Running Speech.

Authors:  Leah K Bowen; Gabrielle L Hands; Sujata Pradhan; Cara E Stepp
Journal:  J Med Speech Lang Pathol       Date:  2013-09

4.  Gastric emptying in healthy volunteers after multiple doses of levodopa.

Authors:  D G Waller; C Roseveare; A G Renwick; B Macklin; C F George
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

5.  Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease.

Authors:  M Contin; R Riva; P Martinelli; F Albani; A Baruzzi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  The influence of levodopa on gastric emptying in man.

Authors:  D R Robertson; A G Renwick; N D Wood; N Cross; B S Macklin; J S Fleming; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

7.  Preventive effect of rikkunshito on gastric motor function inhibited by L-dopa in rats.

Authors:  Lixin Wang; Sachiko Mogami; Hiroshi Karasawa; Chihiro Yamada; Seiichi Yakabi; Koji Yakabi; Tomohisa Hattori; Yvette Taché
Journal:  Peptides       Date:  2014-03-11       Impact factor: 3.750

Review 8.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

9.  Effect of duration of levodopa/decarboxylase inhibitor therapy on the pharmacokinetic handling of levodopa in elderly patients with idiopathic Parkinson's disease.

Authors:  S G Bowes; C J O'Neill; P W Nicholson; A L Leeman; A A Deshmukh; R J Dobbs; S M Dobbs
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  Oral amino acids and gastric emptying: an investigation of the mechanism of levodopa-induced gastric stasis.

Authors:  D G Waller; F Usman; A G Renwick; B Macklin; C F George
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.